NMNorio Miyamura

Norio Miyamura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Norio Miyamura has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Akira Sakamaki

    Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Aasahimachi-Dori, Chuo-ku, Niigata 951-8520, Japan

    1 shared publication
  • Hiromi Miura

    Department of Molecular Life Science, Division of Basic Medical Science and Molecular Medicine, School of Medicine, Tokai University, Isehara 259-1193, Kanagawa, Japan

    1 shared publication
  • Hiroshi Nishina

    Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan

    1 shared publication
  • Hiroteru Kamimura

    Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan

    1 shared publication
  • Hiroyuki Abe

    Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Aasahimachi-Dori, Chuo-ku, Niigata 951-8520, Japan

    1 shared publication
  • Kenya Kamimura

    Department of General Medicine, Niigata University School of Medicine, Niigata 951-9510, Japan

    1 shared publication

Latest Publications

  • Open Access

    Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma

    by Kenya Kamimura, Takeshi Yokoo, Hiroyuki Abe, Norihiro Sakai, Takuro Nagoya, Yuji Kobayashi, Masato Ohtsuka, Hiromi Miura, Akira Sakamaki, Hiroteru Kamimura, et al.

    Hepatocellular carcinoma (HCC) is a major global malignancy, responsible for >90% of primary liver cancers. Currently available therapeutic options have poor performances due to the highly heterogeneous nature of the tumor cells; recurrence is highly probable, and some patients develop resistances to the therapies. Accordingly, the development of a novel therapy is essential. We assessed gene therapy for HCC using a diphtheria toxin fragment A (DTA) gene-expressing plasmid, utilizing a non-viral hydrodynamics-based procedure. The antitumor effect of DTA expression in HCC cell lines (and alpha-fetoprotein (AFP) promoter selectivity) is assessed in vitro by examining HCC cell growth. Moreover, the effect and safety of the AFP promoter-selective DTA expression was examined in vivo using an HCC mice model established by the hydrodynamic gene delivery of the yes-associated protein (YAP)-expressing plasmid. The protein synthesis in DTA transfected cells is inhibited by the disappearance of tdTomato and GFP expression co-transfected upon the delivery of the DTA plasmid; the HCC cell growth is inhibited by the expression of DTA in HCC cells in an AFP promoter-selective manner. A significant inhibition of HCC occurrence and the suppression of the tumor marker of AFP and des-gamma-carboxy prothrombin can be seen in mice groups treated with hydrodynamic gene delivery of DTA, both 0 and 2 months after the YAP gene delivery. These results suggest that DTA gene therapy is effective for HCC.